Inhibikase Therapeutics Inc (NASDAQ: IKT) has spoken about its 15 million shares underwritten public offering. The company dwells on the pricing aspect, outlining that the shares will be sold out at $3 each, a move that will see the company accumulate gross proceeds adding up to $45 million. Focusing on the […]
